Multiple indications for everolimus after liver transplantation in current clinical practice

Table 4 Comparison between patients with hepatocellular carcinoma outside Milan criteria in the explanted liver receiving everolimus and a historical cohort not receiving mTOR inhibitors, and liver-transplanted patients with recurrence of hepatocellular carcinoma receiving everolimus and a historical cohort not receiving mammalian target of rapamycin inhibitors n (%)

HCC outside Milan criteria inexplanted livers	Patients receiving everolimusn = 14	Historical controls without mTORin = 14	P
Recipient age at transplant (yr)	55.5 ± 11.3	56.38 ± 7.1	NS
Recipient sex (male-female) (%)	86-14	79 - 21	NS
Child–Pugh status	6.7 ± 1.8	6.5 ± 1.4	NS
MELD score	13.6 ± 5	11.4 ± 3.4	NS
Size of largest tumour on pathologic exam	3.43 ± 1.50	3.152 ± 1.05	NS
Nº of tumours at pathologic exam	2.70 ± 1.7	2.74 ± 1.7	NS
Microvascular invasion	10 (78)	4 (29)	0.02
Macrovascular invasion	5 (39)	0	0.01
Satellitosis	7 (50)	3 (21.4)	NS
Well-moderately differentiated tumour (%)	31-69	50-50	NS
Mean alpha-fetoprotein	366 ± 771	55 ± 125	NS
Median alpha-fetoprotein	12 (3-2571)	8 (2-445)	NS
HCC treatment while on waiting list	9 (64.3)	8 (57)	NS
Mean donor age in years	59 ± 14.9	58 ± 12.6	NS
Mean and median patient survival post-LT (mo)	56 ± 8.5 (59)	67 ± 11 (54)	NS
HCC recurrence in post-LT follow-up	n = 6	n = 6	P
Recipient age at transplant (yr)	53.6 ± 10	46.5 ± 13	NS
Recipient sex (male-female) (%)	100-0	83-17	NS
Milan criteria in explanted liver (yes-no) (%)	33-67	33-67	NS
Mean donor age (yr)	52.1 ± 16	41 ± 12.8	NS
Months from LT to recurrence	37.9 ± 45	28.5 ± 30	NS
Immunosuppression at recurrence (CyA-FK) (%)	17-83	17-83	NS
Type of recurrence (intra–extrahepatic) (%)	17-83	17-83	NS

HCC: Hepatocellular carcinoma; mTORi: Mammalian target of rapamycin inhibitors; LT: Liver transplantation; CyA: Neoral cyclosporine; FK: Tacrolimus; NS: No significant.